PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Zolmitriptan - Migraine (acute)
PAD Profile : Zolmitriptan - Migraine (acute) Important
Keywords :
Triptans, acute migraine, migraine treatment
Brand Names Include :
Zomig
Important Information :
Prescribe generically
Traffic Light Status
Status 1 of 2.
Status :
Green
Formulations :
- Nasal spray
- Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Status :
Green (see narrative)
Important
Formulations :
- Oro-dispersible
Important Information :
Use orodispersible tablets in patients with swallowing difficulties, nausea or vomitting.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
No guidelines returned.
Other Drugs
- Naratriptan hydrochloride
- Sumatriptan succinate
- Frovatriptan
- Almotriptan
- Eletriptan
- Rizatriptan
- Melatonin
- Rimegepant
- Analgesics with anti-emetics
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
03 May 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
GENERIC Zolmitriptan has been considered by the PCN and has been assigned a GREEN 1st line traffic light status. NOTE - the branded product, Zomig, was considered BLACK at the PCN in May 2017.
Zolmitriptan/ Rizatriptan orodispersible tablets should be considered as a suitable first line treatment for patients when there are difficulties in swallowing the solid dose formulations or the patient has difficulties with nausea and vomiting.
02 March 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
UPDATED: The PCN recommends that sumatriptan, zolmitriptan, rizatriptan and naratriptan should be considered as first line triptans where clinically appropriate and should be prescribed generically.
Associated BNF Codes
04. Central Nervous System
04.07.04. Antimigraine drugs